Parkinson's disease, dopaminergic drugs and the plant world

被引:10
|
作者
Kempster, Peter [1 ,2 ]
Ma, Andrew [1 ]
机构
[1] Monash Med Ctr, Neurosci Dept, Clayton, Vic, Australia
[2] Monash Univ, Sch Clin Sci Med, Clayton, Vic, Australia
关键词
Parkinson's disease; plants; dopamine; levodopa; phytochemicals; L-DOPA; LEVODOPA THERAPY; MUCUNA-PRURIENS; RESERPINE; APOMORPHINE; SEROTONIN; BROMOCRIPTINE; ACCUMULATION; PROLACTIN; REDUCTION;
D O I
10.3389/fphar.2022.970714
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A large proportion of drugs used for the treatment of neurological disorders relate to naturally occurring compounds, many of which are plant alkaloids. This is particularly true of Parkinson's disease (PD). The pharmacopoeia of PD has strong botanical origins, while major discoveries about the neurochemistry of the basal ganglia came from the study of phytochemicals. This article narrates the development of pharmacotherapy for PD in terms of historically important plant-derived substances & mdash;tropane and hamala alkaloids, reserpine, levodopa, apomorphine, and ergoline dopamine receptor agonists. Alkaloids are nitrogen-containing secondary metabolic products that tend to be biologically active. They appear to be involved in plants' adaptation to herbivorous animals, though their exact purpose and the ways in which they work are uncertain. A sizable group of alkaloids influence animal dopaminergic systems, highlighting a key biological relationship. While animals must acquire the energy that plants harness, plants need to engage with the animal attribute that they lack & mdash;movement & mdash;in order to maximize their reproductive fitness. Neuroactive flowering plant compounds have been interacting with vertebrate and invertebrate motor systems for 100 million years. A deep evolutionary connection helps to explain why the pharmacological treatment of PD is imprinted with the power of these mysterious botanical chemicals.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Real-World Driving Data Indexes Dopaminergic Treatment Effects in Parkinson's Disease
    Chang, Jun Ha
    Bhatti, Danish
    Rizzo, Matthew
    Uc, Ergun Y.
    Bertoni, John
    Merickel, Jennifer
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (09): : 1324 - 1332
  • [42] Delayed administration of dopaminergic drugs is not associated with prolonged length of stay of hospitalized patients with Parkinson's disease
    Skelly, Rob
    Brown, Lisa
    Fogarty, Andrew
    PARKINSONISM & RELATED DISORDERS, 2017, 35 : 25 - 29
  • [43] Clinical manifestations of subjective sleep disorders in Chinese patients with Parkinson's disease and their relationship with dopaminergic drugs
    Wu, Dong-Dong
    He, Jing
    Li, Kai
    Liu, Huijing
    Jin, Ying
    Du, Wei
    Ma, Xinxin
    Long, Yunfei
    Li, Shuhua
    Su, Wen
    Chen, Haibo
    EUROPEAN NEUROLOGY, 2023, 86 (06) : 377 - 386
  • [44] Abnormalities of sensorimotor integration to transcranial magnetic stimulation in Parkinson's disease. The effect of dopaminergic drugs
    Tamburin, S.
    Zanette, G.
    Idone, D.
    Manganotti, P.
    Fiaschi, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 : 36 - 36
  • [45] Implications of secondary unresponsiveness to dopaminergic drugs with preserved response to subthalamic nucleus stimulation in Parkinson's disease
    Lenka, Abhishek
    Jhunjhunwala, Ketan R.
    Stezin, Albert
    Manjunath, M.
    Srinivas, Dwarakanath
    Yadav, Ravi
    Pal, Pramod K.
    NEUROLOGY INDIA, 2018, 66 : S135 - S137
  • [46] Sex, drugs and Parkinson's disease
    Ushe, Mwiza
    Perlmutter, Joel S.
    BRAIN, 2013, 136 : 371 - 373
  • [47] Advances in Parkinson's Disease Drugs
    Di Stefano, Antonio
    Marinelli, Lisa
    BIOMOLECULES, 2021, 11 (11)
  • [48] Novel drugs for Parkinson's disease
    Hubble, JP
    MEDICAL CLINICS OF NORTH AMERICA, 1999, 83 (02) : 525 - +
  • [49] New drugs for Parkinson's disease
    Simonson, William
    GERIATRIC NURSING, 2017, 38 (03) : 244 - 245
  • [50] Antidiabetic drugs in Parkinson's disease
    Aguirre-Vidal, Yoshajandith
    Montes, Sergio
    Mota-Lopez, Ana Carolina
    Navarrete-Vazquez, Gabriel
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2024, 11